Vincent Wilson, McFarland Willi
Department of Epidemiology and Biostatistics, Temple University, Philadelphia, PA, United States of America.
San Francisco Department of Public Health, San Francisco, CA, United States of America; Department of Medicine, University of California, San Francisco, CA, United States of America.
Int J Drug Policy. 2022 Dec;110:103873. doi: 10.1016/j.drugpo.2022.103873. Epub 2022 Oct 14.
To identify missed opportunities for healthcare providers to discuss HIV pre-exposure prophylaxis (PrEP) with people who inject drugs (PWID).
Participants were 395 HIV-negative PWID recruited for the 2018 National HIV Behavioral Surveillance survey in San Francisco, California via respondent-driven sampling. Adjusted logistic regression tested whether discussing PrEP with a provider in the last year was associated with sociodemographic characteristics, structural factors, and accessing HIV/STI and substance use treatment services.
Most PWID (86.3%) reported seeing a healthcare provider, but only 15.0% of these reported discussing PrEP with a healthcare provider. PWID who were sexual minority men had greater odds of having a discussion about PrEP with a healthcare provider than PWID who were heterosexual men (aOR=3.42, 95% CI=1.21-9.73) or heterosexual women (aOR=3.69, 95% CI=1.08-12.62). Additionally, factors associated with discussing PrEP included: being tested for HIV (aOR=4.29, 95% CI=1.21-15.29), having a healthcare provider recommend HIV testing (aOR=2.95, 95% CI=1.23-7.06), and receiving free condoms from a prevention program (aOR=5.45, 95% CI=1.78-16.65).
In the face of low PrEP uptake, continuing HIV transmission, and many missed opportunities to discussed PrEP (e.g., PWID who are women, substance use treatment services), these findings from San Francisco indicate that healthcare providers and public health efforts need to systematically offer PrEP to PWID. Additional research may clarify missed opportunities in other locations as well as the impact of COVID-19.
确定医疗服务提供者与注射吸毒者(PWID)讨论HIV暴露前预防(PrEP)时错失的机会。
参与者是通过应答驱动抽样为2018年加利福尼亚州旧金山全国HIV行为监测调查招募的395名HIV阴性的注射吸毒者。调整后的逻辑回归分析检验了去年与医疗服务提供者讨论PrEP是否与社会人口统计学特征、结构因素以及获得HIV/性传播感染和物质使用治疗服务有关。
大多数注射吸毒者(86.3%)报告看过医疗服务提供者,但其中只有15.0%报告与医疗服务提供者讨论过PrEP。性少数男性注射吸毒者与医疗服务提供者讨论PrEP的几率高于异性恋男性注射吸毒者(调整优势比[aOR]=3.42,95%置信区间[CI]=1.21-9.73)或异性恋女性注射吸毒者(aOR=3.69,95%CI=1.08-12.62)。此外,与讨论PrEP相关的因素包括:接受过HIV检测(aOR=4.29,95%CI=1.21-15.29)、有医疗服务提供者推荐进行HIV检测(aOR=2.95,95%CI=1.23-7.06)以及从预防项目获得免费安全套(aOR=5.45,95%CI=1.78-16.65)。
鉴于PrEP的接受率较低、HIV持续传播以及讨论PrEP时存在许多错失的机会(例如女性注射吸毒者、物质使用治疗服务),旧金山的这些研究结果表明,医疗服务提供者和公共卫生工作需要系统地向注射吸毒者提供PrEP。更多研究可能会阐明其他地区错失的机会以及COVID-19的影响。